23andme

Blue Cross Blue Shield insurers are investing in a generic drug venture. The Blue Cross Blue Shield Association (BCBSA) and 18 Blue Cross Blue Shield insurers have invested $55 million to try to increase competition for hospital-based generic drugs. (Reuters)

23andMe has laid off 100 staff as DNA test sales decline. CEO Anne Wojcicki said she was “surprised” by the decreasing interest in consumer DNA tests, citing factors like recession fears and privacy concerns. (CNBC)

Patient advocacy groups often don’t disclose pharma ties, according to a study. The research found that, of groups that receive pharma funding, only 27% disclosed this information on their websites. (STAT)

Another former Insys exec was sentenced. John Kapoor, former chairman of Insys Therapeutics, was sentenced to 26 months in prison for orchestrating a bribery scheme to get doctors to prescribe more opioids. (STAT)

PatientPoint is using its point-of-care network to raise money for Australia. The company is running a PSA to raise money for Australia wildfire relief on its waiting room network. The spot urges viewers to donate to the Red Cross and WIRES. (MM&M)